Bortezomib 3.5 mg

Bortezomib 3.5 mg

Product Overview

Generic NameBortezomib 3.5 mg
Brand Name(s)Biosimilar
CategoryAntineoplastic / Cancer
FormVial, lyophilized powder/injection (IV or SC).
Strength3.5 mg
Therapeutic ClassAntineoplastic (proteasome inhibitor)
ATC CodeL01XG01

Manufacturing & Regulatory

ManufacturerEllia
GMP ComplianceWHO–GMP
DMF/CEPType II
COFEPRIS010.000.4448.00
Free Sale CertificateYes, available as COPP/CPP

Logistics & Export

MOQ10 units
Shelf Life36 months
Storage2–8 °C, protect from light
IncotermsEx-Mexico
Lead Time7 to 10 days

Documentation Available Upon Request

Certificate of Analysis (PDF)Yes—lot-specific Certificate of Analysis
SDS-Safety Data Sheet (PDF)Available upon request from manufacturer/distributor
CTD Summary (PDF)CTD available to regulators; summary available to qualified partners